DCP-001 is under clinical development by Mendus and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect DCP-001’s likelihood of approval (LoA) and phase transition for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) took place on 23 Feb 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their DCP-001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

DCP-001 overview

DCP-001 is under development for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome, high-grade serous ovarian cancer and multiple myeloma. It is administered intradermally and formulated solution and is a dendritic cell vaccine. The drug is developed based on proprietary DCOne platform. The DCOne cell line is derived from a patient with acute myeloid leukemia (AML) and expresses multiple AML-specific antigens.

Mendus overview

Mendus, formerly Immunicum, develops allogeneic and off-the-shelf cell-based therapies for treating solid tumors. The company’s product candidate ilixadencel, an intratumoral immune primer is used for the treatment of renal cell cancer, gastrointestinal stromal tumors, multiple solid tumors, kidney, liver and hepatocellular cancer. Mendus another product DCP-001 is a cancer relapse vaccine that is derived from the DCOne leukemic cell line to treat acute myeloid leukemia and ovarian cancer. The company works in partnership with academic research groups, pharmaceutical and biotech companies to develop and commercialize new therapeutics. It operates a research and development facility at Leiden, The Netherlands. Mendus is headquartered in Stockholm, Sweden.

Quick View DCP-001 LOA Data

Report Segments
  • Innovator
Drug Name
  • DCP-001
Administration Pathway
  • Intradermal
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Mendus
  • Originator: DC Prime
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.